Dashboard
Manage Tickers

BNTXBioNTech SE

Nasdaq biontech.de


$ 89.95 $ 1.13 (1.27 %)    

Wednesday, 01-May-2024 15:59:36 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 422.58 $ -3.07 (-0.72 %)
DIA $ 378.81 $ 0.76 (0.2 %)
SPY $ 500.35 $ -1.63 (-0.32 %)
TLT $ 88.50 $ 0.65 (0.74 %)
GLD $ 213.80 $ 1.92 (0.91 %)
$ 89.95
$ 87.36
$ 0.00 x 0
$ 0.00 x 0
$ 87.28 - $ 90.57
$ 85.21 - $ 125.83
424,426
na
21.38M
$ 0.08
$ 0.02
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

gsk-sees-strong-demand-for-vaccines-and-asthma-drugs-raises-annual-outlook
GSK Sees Strong Demand For Vaccines and As...
05/01/2024 13:42:17

Discover GSK's first-quarter performance, boasting a 10% Y/Y sales surge to £7.4 billion. Notable growth in Vaccines and Sp...

covid-19-patent-dispute-sorted-acuitas-therapeutics-and-curevac-reach-settlement-in-patent-battle
COVID-19 Patent Dispute Sorted: Acuitas Th...
04/26/2024 18:45:00

Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfi...

whats-going-on-with-pfizer-stock-on-thursday
What's Going On With Pfizer Stock On Thurs...
04/25/2024 17:51:32

GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying hig...

moderna-faces-pfizer-biontech-in-london-patent-battle-over-covid-19-vaccines-in-legal-showdown
Moderna Faces Pfizer, BioNTech in London P...
04/23/2024 19:00:34

Moderna challenges Pfizer and BioNTech in a London patent trial over mRNA vaccine patents. The outcome may reshape the pharmace...

assessing-biontech-insights-from-11-financial-analysts
Assessing BioNTech: Insights From 11 Finan...
04/17/2024 14:00:53

hc-wainwright--co-reiterates-buy-on-biontech-maintains-107-price-target
HC Wainwright & Co. Reiterates Buy on BioN...
04/17/2024 10:24:03

HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $107 price target.

reported-sunday-biontech-three-year-phase-1-follow-up-data-for-mrna-based-individualized-immunotherapy-candidate-shows-persistence-of-immune-response-and-delayed-tumor-recurrence-in-some-patients-with-resected-pancreatic-cancer
Reported Sunday, BioNTech Three-Year Phase...
04/08/2024 06:45:52

Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate auto...

curevac-gsk-partner-release-data-on-influenza-vaccine-study
CureVac, GSK Partner Release Data On Influ...
04/04/2024 16:18:36

CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen c...

ubs-maintains-neutral-on-biontech-lowers-price-target-to-101
UBS Maintains Neutral on BioNTech, Lowers ...
03/27/2024 18:14:24

UBS analyst Eliana Merle maintains BioNTech (NASDAQ:BNTX) with a Neutral and lowers the price target from $110 to $101.

jp-morgan-maintains-underweight-on-biontech-lowers-price-target-to-90
JP Morgan Maintains Underweight on BioNTec...
03/22/2024 16:37:14

JP Morgan analyst Jessica Fye maintains BioNTech (NASDAQ:BNTX) with a Underweight and lowers the price target from $99 to $90.

bmo-capital-maintains-outperform-on-biontech-lowers-price-target-to-123
BMO Capital Maintains Outperform on BioNTe...
03/21/2024 17:21:20

BMO Capital analyst Etzer Darout maintains BioNTech (NASDAQ:BNTX) with a Outperform and lowers the price target from $127 to...

cracking-the-code-understanding-analyst-reviews-for-biontech
Cracking The Code: Understanding Analyst R...
03/21/2024 16:01:08

canaccord-genuity-reiterates-buy-on-biontech-maintains-171-price-target
Canaccord Genuity Reiterates Buy on BioNTe...
03/21/2024 15:33:30

Canaccord Genuity analyst Bill Maughan reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $171 price target.

why-lifecore-biomedical-shares-are-trading-lower-by-around-32-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Lifecore Biomedical Shares Are Trading...
03/20/2024 18:03:46

Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it con...

biontech-touts-its-oncology-shift-after-reporting-disappointing-fourth-quarter-financials
BioNTech Touts Its Oncology Shift After Re...
03/20/2024 17:38:52

BioNTech SE (NASDAQ: BNTX) is way past its glorious Covid-19 days, when it thrived with Pfizer Inc (NYSE: PFE) for saving the w...

why-is-biontech-stock-trading-lower-on-wednesday
Why Is BioNTech Stock Trading Lower On Wed...
03/20/2024 12:43:05

BioNTech reported Q4 2023 earnings below expectations, with EPS at €1.90 vs. €9.26 last year. Sales were €1.479 billion, missin...

us-stock-futures-stall-as-traders-await-fed-chair-powells-decision-analyst-sees-sp-500-showing-signs-of-near-term-top
US Stock Futures Stall As Traders Await Fe...
03/20/2024 11:28:21

Investors remain cautious ahead of the Federal Reserve‘s interest rate decision, with stock futures on Wednesday hinting at a l...

biontech-expects-fy2024-sales-of-25b-31b-with-rd-expenses-of-24b-26b-sga-expenses-of-700m-800m-and-capital-expenditure-of-400m-500m
BioNTech Expects FY2024 Sales Of €2.5B-€3....
03/20/2024 10:20:05

biontech-delivered-over-400m-covid-19-vaccine-doses-worldwide-in-2023-including-xbb15-variant-adapted-monovalent-covid-19-vaccine
BioNTech Delivered Over 400M Covid-19 Vacc...
03/20/2024 10:17:53

biontech-q4-gaap-eps-204-misses-264-estimate-sales-159b-miss-199b-estimate
BioNTech Q4 GAAP EPS $2.04 Misses $2.64 Es...
03/20/2024 10:16:52

BioNTech (NASDAQ:BNTX) reported quarterly earnings of $2.04 per share which missed the analyst consensus estimate of $2.64 by 2...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION